- ROUNDTABLE: Pharmacy’s future in sync with technology
- EXPERT BLOG: Provider status for pharmacists — one way or another
- Senate passes Drug Quality and Security Act
- CDC publishes guidelines for collaborative practice agreements
- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
FLORHAM PARK, N.J. — A treatment made by Shionogi for chronic, severe drooling in children and teenagers with neurological conditions has become available, the drug maker said Thursday.
Shionogi announced the availability of Cuvposa (glycopyrrolate) oral solution for children ages 3 to 16 years with such conditions as cerebral palsy. The company also has a partnership with Diplomat Specialty Pharmacy to grant caregivers convenient access to the drug through a patient’s physician, allowing Diplomat to fill the prescription and ship the drug once the physician places an order and it’s verified.
“Shionogi is proud to expand its mission of helping to bring high-quality care to pediatric patients by introducing Cuvposa to the U.S. market,” Shionogi chief medical officer Donald Manning said. “Unlike tablet formulations, liquid Cuvposa does not require compounding by a pharmacist before it is administered by caregivers, providing families with a new approach to treating chronic, severe drooling in children and adolescents with neurologic conditions.”